Mizuho analyst Uy Ear initiated coverage of Cartesian Therapeutics with a Buy rating and $40 price target. The analyst believes the company’s’ “safer” mRNA CAR-T approach is well positioned to compete in the emerging cell therapy autoimmune disease landscape, and its lead asset, Descartes-08, could be first-in-class in the $1B myasthenia gravis opportunity. The firm says Cartesian is “under the radar” and the next potential catalyst — the mid-2024 Phase 2b readout of Descartes-08 in MG — should generate broader interest.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAC:
- Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis
- Cartesian receives FDA RMAT designation for Descartes-08 for treatment of MG
- Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
- Cartesian Therapeutics Provides Business Updates at Industry Events
- Cartesian reports Q1 EPS ($10.50) vs ($4.24) last year